Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors

References

• Meier J, Sturm A. Current treatment of ulcerative colitis. World J Gastroenterol. 2011;17:3204–3212.
   PubMed Web of Science ®Google Scholar
• Ham M, Moss AC. Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev Clin Pharmacol. 2012;5:113–123.
   PubMed Web of Science ®Google Scholar
• Kornbluth A, Sachar DB. The Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501–523.
   PubMed Web of Science ®Google Scholar
• Langan RC, Gotsch PB, Krafczyk MA, et al. Ulcerative colitis: diagnosis and treatment. Am Fam Physician. 2007;76:1323–1330.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR. Mesalamine in the treatment of ulcerative colitis: novel therapeutic options. Gastroenterol Hepatol. 2009;5:65–73.
   Google Scholar
• Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006;23:577–585.
   PubMed Web of Science ®Google Scholar
• Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114:39–43.
   PubMed Web of Science ®Google Scholar
• Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18:191–198.
   PubMed Web of Science ®Google Scholar
• Oliveira L, Cohen RD. Maintaining remission in ulcerative colitis - role of once daily extended-release mesalamine. Drug Des Devel Ther. 2011;5:111–116.
   PubMed Web of Science ®Google Scholar
• Prantera C, Rizzi M. 5-ASA in ulcerative colitis: improving treatment compliance. World J Gastroenterol. 2009;15:4353–4355.
   PubMed Web of Science ®Google Scholar
• Salix Pharmaceuticals, Inc. Apriso^® (mesalamine) extended-release capsules [package insert]. Raleigh, NC: Salix Pharmaceuticals, Inc.; 2012.
   Google Scholar
• Lichtenstein GR, Gordon GL, Zakko S, et al. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trial. Aliment Pharmacol Ther. 2010;32:990–999.
   PubMed Web of Science ®Google Scholar
• Gordon GL, Zakko S, Murthy U, et al. Once-daily mesalamine formulation for maintenance of remission in ulcerative colitis: a randomized, placebo-controlled clinical trial [published online ahead of print September 11, 2015]. J Clin Gastroenterol. 2015. doi:10.1097/MCG.0000000000000414.
   PubMed Web of Science ®Google Scholar
• Sutherland LR, Martin F, Greer S, et al. 5-aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92:1894–1898.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Zakko S, Gordon GL, et al. Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials. Aliment Pharmacol Ther. 2012;36:126–134.
   PubMed Web of Science ®Google Scholar
• Dignass AU, Bokemeyer B, Adamek H, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:762–769.
   PubMed Web of Science ®Google Scholar
• Kane S, Katz S, Jamal MM, et al. Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis. Inflamm Bowel Dis. 2012;18:1026–1033.
   PubMed Web of Science ®Google Scholar
• Kruis W, Jonaitis L, Pokrotnieks J, et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Aliment Pharmacol Ther. 2011;33:313–322.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Korzenik J, Lashner B, et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology. 2010;138:1286–1296.
   PubMed Web of Science ®Google Scholar
• Höie O, Wolters F, Riis L, et al. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol. 2007;102:1692–1701.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Jung ES, Lee JH, et al. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with mild-to-moderate ulcerative colitis. Hepatogastroenterology. 2012;59:1415–1420.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005;100:2478–2485.
   PubMed Web of Science ®Google Scholar
• Meucci G, Fasoli R, Saibeni S, et al. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. Inflamm Bowel Dis. 2012;18:1006–1010.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Ferrante M, Magro F, et al. Results from the 2nd Scientific Workshop of the ECCO. I: impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis. 2011;5::477–483.
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Cassinotti A, Duca P, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2011;9:483–489.
   PubMed Web of Science ®Google Scholar
• Walsh A, Palmer R, Travis S. Mucosal healing as a target of therapy for colonic inflammatory bowel disease and methods to score disease activity. Gastrointest Endosc Clin N Am. 2014;24:367–378.
   PubMedGoogle Scholar
• Loftus EV Jr., Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2004;19:179–189.
   PubMed Web of Science ®Google Scholar
• Corrigan G, Stevens PE. Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther. 2000;14:1–6.
   PubMed Web of Science ®Google Scholar
• Muller AF, Stevens PE, McIntyre AS, et al. Experience of 5-aminosal-icylate nephrotoxicity in the United Kingdom. Aliment Pharmacol Ther. 2005;21:1217–1224.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, González-Lama Y, Maté J. 5-aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2007;13:629–638.
   PubMed Web of Science ®Google Scholar
• Yen L, Wu J, Hodgkins PL, et al. Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis. J Manag Care Pharm. 2012;18:701–712.
   PubMed Web of Science ®Google Scholar
• Lachaine J, Yen L, Beauchemin C, et al. Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database. BMC Gastroenterol. 2013;13:23.
   PubMed Web of Science ®Google Scholar